Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
In situ metabolomics in cancer by mass spectrometry imaging.
Adv. Cancer Res. 134, 117-132 (2017)
Metabolomics is a rapidly evolving and a promising research field with the expectation to improve diagnosis, therapeutic treatment prediction, and prognosis of particular diseases. Among all techniques used to assess the metabolome in biological systems, mass spectrometry imaging is the method of choice to qualitatively and quantitatively analyze metabolite distribution in tissues with a high spatial resolution, thus providing molecular data in relation to cancer histopathology. The technique is ideally suited to study tissues molecular content and is able to provide molecular biomarkers or specific mass signatures which can be used in classification or the prognostic evaluation of tumors. Recently, it was shown that FFPE tissue samples are also suitable for metabolic analyses. This progress in methodology allows access to a highly valuable resource of tissues believed to widen and strengthen metabolic discovery-driven studies.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
6.267
1.801
15
16
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
Diagnostic ; Ffpe Tissue ; Maldi ; Mass Spectrometry Imaging ; Metabolomics ; Predictive ; Prognostic Pathology; Predictive Molecular Pathology; Intratumor Heterogeneity; Breast-cancer; Biomarker Discovery; Clinical-relevance; Tissue-sections; Gastric-cancer; Diagnosis; Tumors; Cells
Sprache
englisch
Veröffentlichungsjahr
2017
Prepublished im Jahr
2016
HGF-Berichtsjahr
2016
ISSN (print) / ISBN
0065-230x
Zeitschrift
Advances in Cancer Research
Quellenangaben
Band: 134,
Seiten: 117-132
Verlag
Elsevier
Verlagsort
San Diego
Begutachtungsstatus
Peer reviewed
Institut(e)
Research Unit Analytical Pathology (AAP)
POF Topic(s)
30205 - Bioengineering and Digital Health
Forschungsfeld(er)
Enabling and Novel Technologies
PSP-Element(e)
G-500390-001
WOS ID
WOS:000403247100006
Scopus ID
85008225573
Erfassungsdatum
2016-12-31